DGAP-News: Apricus Biosciences Announces Poster Presentation of Femprox(R) Phase III Clinical Data at American Urological Association Annual Meeting
Apricus Biosciences, Inc.
04.05.2012 16:05
—————————————————————————
SAN DIEGO, 2012-05-04 16:05 CEST (GLOBE NEWSWIRE) —
Apricus Biosciences, Inc. (–Apricus Bio– or the –Company–) (Nasdaq:APRI)
(http://www.apricusbio.com) announced today a poster titled, –Updated analyses
of randomized, double-blind, Phase 3 study of Femprox(r), an alprostadil cream
with a novel transdermal delivery technology for the treatment of female sexual
arousal d
